Investigational Drug Information for Telaglenastat
✉ Email this page to a colleague
What is the drug development status for Telaglenastat?
Telaglenastat is an investigational drug.
There have been 16 clinical trials for Telaglenastat.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 14th 2018.
The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Renal Cell. The leading clinical trial sponsors are Calithera Biosciences, Inc, National Cancer Institute (NCI), and Novotech (Australia) Pty Limited.
There are seventeen US patents protecting this investigational drug and one hundred and seventy-six international patents.
Summary for Telaglenastat
| US Patents | 17 |
| International Patents | 176 |
| US Patent Applications | 76 |
| WIPO Patent Applications | 31 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 2 (2018-05-14) |
| Vendors | 55 |
Recent Clinical Trials for Telaglenastat
| Title | Sponsor | Phase |
|---|---|---|
| Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | Calithera Biosciences, Inc | Phase 2 |
| Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | National Cancer Institute (NCI) | Phase 2 |
| Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | Washington University School of Medicine | Phase 2 |
Clinical Trial Summary for Telaglenastat
Top disease conditions for Telaglenastat
Top clinical trial sponsors for Telaglenastat
US Patents for Telaglenastat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Telaglenastat | ⤷ Sign Up | Combination therapy with glutaminase inhibitors | Calithera Biosciences, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| Telaglenastat | ⤷ Sign Up | Compositions and methods of treating cancer harboring PIKC3A mutations | Case Western Reserve University (Cleveland, OH) | ⤷ Sign Up |
| Telaglenastat | ⤷ Sign Up | Combination therapy with glutaminase inhibitors and immuno-oncology agents | Calithera Biosciences, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| Telaglenastat | ⤷ Sign Up | Combination therapy with glutaminase inhibitors | Calithera Biosciences, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| Telaglenastat | ⤷ Sign Up | Crystal forms of glutaminase inhibitors | Calithera Biosciences, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| Telaglenastat | ⤷ Sign Up | Treatment of lung cancer with inhibitors of glutaminase | Calithera Biosciences, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| Telaglenastat | ⤷ Sign Up | Crystal forms of glutaminase inhibitors | Calithera Biosciences, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Telaglenastat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Telaglenastat | China | CN109982703 | 2036-08-25 | ⤷ Sign Up |
| Telaglenastat | European Patent Office | EP3503893 | 2036-08-25 | ⤷ Sign Up |
| Telaglenastat | Japan | JP2019524852 | 2036-08-25 | ⤷ Sign Up |
| Telaglenastat | World Intellectual Property Organization (WIPO) | WO2018039441 | 2036-08-25 | ⤷ Sign Up |
| Telaglenastat | Australia | AU2016335991 | 2035-10-05 | ⤷ Sign Up |
| Telaglenastat | Canada | CA3000996 | 2035-10-05 | ⤷ Sign Up |
| Telaglenastat | China | CN108601767 | 2035-10-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
